merger

AT&T said Monday that it is ending its $39 billion bid to buy T-Mobile USA after facing fierce government objections. The cellphone giant said that the actions of the government to block the deal do not change the challenges of the wireless phone industry, which it says requires more airwaves, known as spectrum, to expand. The deal would have solved that problem for a time, and without it, "customers will be harmed and needed investment will be stifled," AT&T said in a statement.

The American Customer Satisfaction Index's annual report on airlines showed Southwest still on top of the rankings, and far ahead of No. 2 Continental. Southwest even improved its score, a rare bright spot in an industry that came in last overall in customer satisfaction among those the ACSI rates.

Nasdaq and IntercontinentalExchange are withdrawing their $11 billion bid for the New York Stock Exchange after recognizing that it wouldn't receive regulatory approval. The decision leaves the path open for NYSE Euronext to merge with the German exchange operator Deutsche Boerse.

Mergers and acquisitions are becoming ever more popular, with activity up 24% in the first two months of this year -- after already growing 23% in 2010. Here's how your portfolio can benefit from this trend.

The longtime coffee rivals may be discussing a merger that could provide the smaller player with a boost in the single-cup market. And Peet's, which has longstanding deals with grocery chains, could steer Starbucks towards a smoother grocery distribution strategy.

SprintNextel and T-Mobile USA are reportedly discussing another tie-up, as both companies seek to stop the flow of customers defecting to larger cell-phone service providers. In the past, the carriers have mulled a merger but haven't been able to agree on who would acquire whom.

Motorola's sale of its network-equipment division to Nokia Siemens Networks seems to have hit another hiccup. Chinese telecom-equipment maker Huawei has won a preliminary U.S. court injunction against Motorola, a Huawei vendor, arguing that the deal would transfer confidential information to a competitor.

French drug company Sanofi-Aventis (SNY) has finally made a deal to buy biotech company Genzyme (GENZ) for $20.1 billion, about $74 a share. Genzyme shareholders will get a contingent value right that represents potential future payments if Lemtrada, the company's multiple sclerosis drug, is a...

Nothing like a big media deal to spark commentary from the media. And indeed, there's been no shortage of reaction -- from praise to pillory -- to AOL's decision to purchase upstart news site The Huffington Post for $315 million, mostly in cash.

It seems that months of merger talks between French pharma Sanofi-Aventis and U.S. biotech Genzyme have entered the home stretch. This week, Sanofi is expected to offer $74 a share for Genzyme, with an option included potentially worth $5 to $6 a share.